Halozyme Therapeutics/$HALO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Halozyme Therapeutics
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Ticker
$HALO
Sector
Primary listing
Employees
350
Headquarters
Website
HALO Metrics
BasicAdvanced
$8B
14.42
$4.74
0.96
-
Price and volume
Market cap
$8B
Beta
0.96
52-week high
$79.50
52-week low
$42.01
Average daily volume
2M
Financial strength
Current ratio
1.587
Quick ratio
1.252
Long term debt to equity
158.771
Total debt to equity
299.804
Interest coverage (TTM)
41.53%
Profitability
EBITDA (TTM)
813.284
Gross margin (TTM)
78.91%
Net profit margin (TTM)
47.91%
Operating margin (TTM)
59.33%
Effective tax rate (TTM)
20.17%
Revenue per employee (TTM)
$3,550,000
Management effectiveness
Return on assets (TTM)
21.24%
Return on equity (TTM)
124.50%
Valuation
Price to earnings (TTM)
14.421
Price to revenue (TTM)
6.706
Price to book
15.93
Price to tangible book (TTM)
-30.7
Price to free cash flow (TTM)
13.835
Free cash flow yield (TTM)
7.23%
Free cash flow per share (TTM)
4.937
Growth
Revenue change (TTM)
31.19%
Earnings per share change (TTM)
56.68%
3-year revenue growth (CAGR)
28.88%
10-year revenue growth (CAGR)
27.07%
3-year earnings per share growth (CAGR)
47.47%
10-year earnings per share growth (CAGR)
30.41%
What the Analysts think about HALO
Analyst ratings (Buy, Hold, Sell) for Halozyme Therapeutics stock.
Bulls say / Bears say
Halozyme’s acquisition of Elektrofi in a deal valued at up to $900 million expands its drug delivery lineup by adding Hypercon technology to its proprietary platforms, bolstering its market offering (Reuters)
The Elektrofi Hypercon platform enables biologic drugs to be formulated at 400–500 mg/ml while still remaining easy to inject, meeting growing demand for high-concentration subcutaneous therapies (Reuters)
By structuring $150 million of the transaction as milestone payments tied to three distinct product approvals, Halozyme aligns its financial commitments with regulatory success, mitigating upfront risk and incentivizing development (Reuters)
Up to $150 million in contingent milestone payments depend on regulatory approvals of three separate products, introducing uncertainty around the timing and realization of the acquisition’s full value (Reuters)
Integrating Elektrofi and commercializing its nascent Hypercon platform carries execution risks; at a total valuation of up to $900 million, Halozyme may risk overpaying if adoption of the technology lags expectations (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
HALO Financial Performance
Revenues and expenses
HALO Earnings Performance
Company profitability
HALO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Halozyme Therapeutics stock?
Halozyme Therapeutics (HALO) has a market cap of $8B as of November 06, 2025.
What is the P/E ratio for Halozyme Therapeutics stock?
The price to earnings (P/E) ratio for Halozyme Therapeutics (HALO) stock is 14.42 as of November 06, 2025.
Does Halozyme Therapeutics stock pay dividends?
No, Halozyme Therapeutics (HALO) stock does not pay dividends to its shareholders as of November 06, 2025.
When is the next Halozyme Therapeutics dividend payment date?
Halozyme Therapeutics (HALO) stock does not pay dividends to its shareholders.
What is the beta indicator for Halozyme Therapeutics?
Halozyme Therapeutics (HALO) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.